Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cytarabine
/ administration & dosage
Female
Follow-Up Studies
Humans
Induction Chemotherapy
/ mortality
Lenalidomide
/ administration & dosage
Leukemia, Myeloid, Acute
/ drug therapy
Male
Myelodysplastic Syndromes
/ drug therapy
Prognosis
Remission Induction
Survival Rate
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
10
2019
accepted:
22
01
2020
revised:
24
12
2019
pubmed:
6
2
2020
medline:
28
10
2020
entrez:
6
2
2020
Statut:
ppublish
Résumé
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome. After establishing a safe lenalidomide, dose elderly patients with AML were randomly assigned in this randomized Phase 2 study (n = 222) to receive standard chemotherapy ("3 + 7") with or without lenalidomide at a dose of 20 mg/day 1-21. In the second cycle, patients received cytarabine 1000 mg/m
Identifiants
pubmed: 32020044
doi: 10.1038/s41375-020-0725-0
pii: 10.1038/s41375-020-0725-0
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Lenalidomide
F0P408N6V4
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1751-1759Investigateurs
D A Breems
(DA)
None Havelange
M-C Vekemans
(MC)
I Moors
(I)
F van Obberg
(F)
J A Maertens
(JA)
B Hodossy
(B)
S Vansteenweghen
(S)
L Lammertijn
(L)
D Deeren
(D)
C Graux
(C)
A Sonet
(A)
A Triffet
(A)
B T Gjertsen
(BT)
M Bargetzi
(M)
J Passweg
(J)
D Heim
(D)
San Giovanni
(S)
Georg Stuessi
(G)
T Pabst
(T)
D Betticher
(D)
Y Chalandon
(Y)
O Spertini
(O)
M Gregor
(M)
U Hess
(U)
M Fehr
(M)
M G Manz
(MG)
S K Klein
(SK)
B J Biemond
(BJ)
G J Ossenkoppele
(GJ)
A van de Loosdrecht
(A)
J J W M Janssen
(JJWM)
J W J van Esser
(JWJ)
M Van der Klift
(M)
R E Brouwer
(RE)
D Van Lammeren-Venema
(D)
M D Levin
(MD)
L W Tick
(LW)
M C J C Legdeur
(MCJC)
G Huls
(G)
E Vellenga
(E)
M Hoogendoorn
(M)
J H Veelken
(JH)
P A von dem Borne
(PA)
H C Schouten
(HC)
O de Weerdt
(O)
W J F M van der Velden
(WJFM)
J Cornelissen
(J)
M Jongen-Lavrencic
(M)
B Wouters
(B)
H G M Raaijmakers
(HGM)
B Löwenberg
(B)
J Kuball
(J)
A Van Rhenen
(A)
M Van Marwijk Kooy
(M)
Commentaires et corrections
Type : ErratumIn
Références
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.
doi: 10.1056/NEJMra1406184
Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125:767–74.
doi: 10.1182/blood-2014-08-551499
Krug U, Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, et al. Therapy of older persons with acute myeloid leukaemia. Leuk Res. 2017;60:1–10.
doi: 10.1016/j.leukres.2017.05.020
Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) et al. Therapy of older persons with acute myeloid leukaemia. Leuk Res. 2017;60:1–10.
doi: 10.1016/j.leukres.2017.05.020
Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A. Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(Sep):1235–48.
doi: 10.1056/NEJMoa0901409
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Acute Leukemia French Association. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–16.
doi: 10.1016/S0140-6736(12)60485-1
Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, French Innovative Leukemia Organization, et al; Improved survival by adding lomustine to conventional chemotherapy for elderly patients with aml without unfavorable cytogenetics: results of the LAM-SA 2007 FILO trial. J Clin Oncol. 2018:JCO2018787366. https://doi.org/10.1200/JCO.2018.78.7366.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684–92.
doi: 10.1200/JCO.2017.77.6112
Levin-Epstein R, Oliai C, Schiller G. Allogeneic hematopoietic stem cell transplantation for older patients with acute myeloid leukemia. Curr Treat Options Oncol. 2018;19:63.
doi: 10.1007/s11864-018-0577-2
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36 https://doi.org/10.1186/1756-8722-2-36
doi: 10.1186/1756-8722-2-36
pubmed: 19674465
pmcid: 2736171
Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117:1828–33.
doi: 10.1182/blood-2010-07-297143
Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br J Haematol. 2017;176:241–7.
doi: 10.1111/bjh.14407
Griffiths EA, Brady WE, Tan W, Vigil CE, Thompson JE, Ford LA, et al. A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Leuk Res. 2016;43:44–8.
doi: 10.1016/j.leukres.2016.02.003
DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, et al. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018;93:254–61.
doi: 10.1002/ajh.24968
Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017;129:1636–45.
doi: 10.1182/blood-2016-10-740613
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–9.
doi: 10.1200/JCO.2012.45.9628
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
doi: 10.1182/blood-2016-08-733196
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31.
doi: 10.1182/blood-2017-04-779405
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98.
doi: 10.1056/NEJMoa1716984
Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889–903.
doi: 10.1016/S1470-2045(18)30240-7
Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a Phase Ib/II Study. J Clin Oncol. 2019:JCO1801600. https://doi.org/10.1200/JCO.18.01600.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
doi: 10.1182/blood-2018-08-868752
Beyar-Katz O, Gill S. Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res. 2018;24:5502–15.
doi: 10.1158/1078-0432.CCR-17-3016